Faculty, Staff and Student Publications
Publication Date
1-1-2023
Journal
Frontiers in Immunology
Abstract
Pyrolyzed deketene curcumin GO-Y022 prevents carcinogenesis in a gastric cancer mouse model. However, it is still less clear if GO-Y022 affects tumor-induced immune suppression. In this study, we found that GO-Y022 inhibited Treg generation in the presence of transforming growth factor beta 1 (TGF-β). However, GO-Y022 showed less impact on Foxp3+ Tregs in the gastric tumor microenvironment. Gastric tumor cells produce a large amount of L-lactate in the presence of GO-Y022 and diminish the inhibitory role of GO-Y022 against Treg generation in response to TGF-β. Therefore, naïve CD4+ T cells co-cultured with GO-Y022 treated gastric tumor cells increased Treg generation. GO-Y022-induced tumor cell death was further enhanced by 2-deoxy-d-glucose (2DG), a glycolysis inhibitor. Combination treatment of GO-Y022 and 2DG results in reduced L-lactate production and Treg generation in gastric tumor cells. Overall, GO-Y022-treatment with restricted glucose metabolism inhibits gastric tumor cell survival and promotes anti-tumor immunity.
Keywords
tumor microenvironment, stomach neoplasms, adenosine triphosphate, glycolysis, regulatory T cells
DOI
10.3389/fimmu.2023.1049713
PMID
36814928
PMCID
PMC9939626
PubMedCentral® Posted Date
February 2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Allergy and Immunology Commons, Bioinformatics Commons, Biomedical Informatics Commons, Digestive System Diseases Commons, Gastroenterology Commons, Medical Sciences Commons, Oncology Commons